title: Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin.
abstract: BACKGROUND
  Ampullary cancer (AC) was classified as pancreatobiliary, intestinal, or other subtype based on the expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20). We aimed to explore the association of AC subtype with patient prognosis.
  
  
  METHODS
  The relationship of AC subtype and expression of Osteopontin (OPN) with the prognosis of 120 AC patients after pancreaticoduodenectomy was investigated.
  
  
  RESULTS
  The patients had pancreatobiliary (CK7+/CK20-, n = 24, 20%), intestinal (CK7-/CK20+, n = 29, 24.2%) or other (CK7+/CK20+ or CK7-/CK20-, n = 67, 55.8%) subtypes of AC, and their median survival times were 23 ± 4.2, 38 ± 2.8 and 64 ± 16.8 months, respectively. The survival times of 64 OPN- patients (53.3%) and 56 OPN+ patients (46.7%) were 69 ± 18.4 and 36 ± 1.3 months, respectively. There was no significant effect of AC subtype on survival of OPN- patients. For OPN+ patients, those with pancreatobiliary AC had a shorter survival time (22 ± 6.6 months) than those with intestinal AC (37 ± 1.4 months, p = 0.041), and other AC subtype (36 ± 0.9 months, p = 0.010); intestinal and other AC subtypes had similar survival times.
  
  
  CONCLUSIONS
  The prognosis of AC patients can be estimated based on immunohistochemical classification and OPN status.
authors: Hospital & Institute of Hepatobiliary Surgery, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China.
authors: Xiang-Qian
authors: XQ
authors: Zhao
authors: Jia-Hong
authors: JH
authors: Dong
authors: Wen-Zhi
authors: WZ
authors: Zhang
authors: Zhe
authors: Z
authors: Liu
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D014670:Ampulla of Vater / Q000473:pathology*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism; D003138:Common Bile Duct Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007414:Intestinal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D053208:Kaplan-Meier Estimate; D053554:Keratin-20 / Q000096:biosynthesis; D053552:Keratin-7 / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D053495:Osteopontin / Q000096:biosynthesis*; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; D053554:Keratin-20; D053552:Keratin-7; D053495:Osteopontin